Kerala Researchers Develop Nanopore Sensors for Early Parkinson's Detection

Researchers at the BRIC-Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram have engineered a novel nanopore-based sensing technology designed to enable early detection and ongoing monitoring of neurodegenerative conditions such as Parkinson's disease and amyotrophic lateral sclerosis. The development addresses a major diagnostic hurdle by creating an analytical tool capable of isolating specific disease markers from background biological noise with high analytical sensitivity.

Epidemiological surveys across India report crude Parkinson's disease prevalence rates. Early diagnosis faces bottlenecks because motor symptoms manifest only after significant dopaminergic loss.

The Biotechnology Research and Innovation Council was formed by subsuming autonomous Department of Biotechnology institutes under a centralized governance body. The nanopore sensors perform label-free single-molecule electrical detection distinguishing disease-specific mutants.

The research effort was spearheaded by Mahendran K.R., working alongside doctoral student Varsha Shaji and postdoctoral researcher Neethu Puthumadathil. According to institutional statements released by the facility, the team successfully designed self-assembling dual-diameter nanopore sensors configured to detect minute quantities of pathological biomarkers that typically evade standard diagnostic screening procedures during early disease stages.

The technological mechanism relies on self-assembling dual-diameter nanopore structures that interact directly with molecular targets. Beyond merely registering the presence of targeted proteins or peptides, the sensors are engineered to distinguish disease-linked biomarkers from harmless biological molecules circulating in biofluids. This selective differentiation capacity represents a crucial technical requirement for reducing false-positive rates in clinical diagnostics.

Early identification of neurodegenerative conditions remains a primary clinical objective because therapeutic interventions are substantially more effective when administered before extensive neuronal degradation occurs. By detecting protein aggregation or related molecular indicators at preliminary stages, the sensors could eventually facilitate timely clinical management strategies for patients.

The project involved institutional partnerships spanning international and domestic research groups, including academic collaborators in Germany and Kolkata. Financial backing for the development was provided through competitive Indian science grants earmarked for advanced biotechnology initiatives.

BRIC-RGCB director Beena Pillai highlighted the broader implications of merging nanoscale engineering with biological sciences, noting that interdisciplinary approaches are essential for addressing complex neurological disorders. As the project progresses beyond the initial design phase, the research team aims to refine the sensor architecture for broader analytical applications and potential clinical validation workflows.